Sound efficacy of prophylactic HPV vaccination: Basics and implications

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 995-996

  Lehtinen, Matti ^a   Paavonen, Jorma ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; CLINICAL RESEARCH; CROSS PROTECTION; CROSS REACTION; CRYSTAL STRUCTURE; DRUG EFFICACY; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; UTERINE CERVIX CANCER;

EID: 84866602709     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20011     Document Type: Article

References (10)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC MonogrEvalCarcinog Risks Hum 2007; 90:1-636; PMID:18354839.
2. Auvinen E, Niemi M, Malm C, Zilliacus R, Trontti A, Fingerroos R, et al. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005; 37:873-6; PMID:16308223; http://dx.doi.org/10.1080/00365540500333566.
3. Dürst M, Gissmann L, Ikenberg H, zurHausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80:3812-5; PMID:6304740; http://dx.doi.org/10.1073/pnas.80.12.3812.
4. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180- 4; PMID:1334560; http://dx.doi.org/10.1073/ pnas.89.24.12180.
5. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al.; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645- 51; PMID:12444178; http://dx.doi.org/10.1056/ NEJMoa020586.
6. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04- adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http:// dx.doi.org/10.1016/S1470-2045(11)70286-8.
7. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al; HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/S1470-2045(11)70287-X.
8. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007; 282:31803-11; PMID:17804402; http://dx.doi.org/10.1074/jbc. M706380200.
9. Rizk RZ, Christensen ND, Michael KM, Müller M, Sehr P, Waterboer T, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008; 89:117-29; PMID:18089735; http://dx.doi.org/10.1099/vir.0.83145-0.
10. Lehtinen M, French K, Dillner J, Paavonen J, Garnett G. Sound implementation of human papillomavirus vaccination as a community-randomized trial. Future Med 2008; 5:289-94.